Compare
Axalta Coating Systems Ltd. vs Albemarle Corp vs BeOne Medicines Ltd. vs Elanco Animal Health Inc
| Latest fiscal year | Axalta Coating Systems Ltd. AXTA | Albemarle Corp ALB | BeOne Medicines Ltd. ONC | Elanco Animal Health Inc ELAN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $5.12B | $5.14B | $5.34B | $4.71B |
| Revenue growth (YoY) | -3.0% | -4.4% | +40.2% | +6.2% |
| Gross margin | 34.4% (computed) | 13.0% | 87.5% | 55.0% |
| Operating margin | 14.4% | -7.1% | 8.4% | n/a |
| Net margin | 7.4% | -9.9% | 5.4% | -4.9% |
| Net income | $378.00M | -$510.63M | $286.93M | -$232.00M |
| EPS (Diluted) | $1.74 | -$5.76 | $0.19 | -$0.47 |
| Operating cash flow | $649.00M | $1.28B | $1.13B | $560.00M |
| Free cash flow | $453.00M | $692.47M | $941.74M | $284.00M |
| Cash & equivalents | $657.00M | n/a | $4.55B | $545.00M |
| Total assets | $7.60B | $16.37B | $8.19B | $13.36B |
| Total liabilities | $5.21B | n/a | $3.83B | $6.81B |
| Shareholders' equity | $2.39B | $9.78B | $4.36B | $6.55B |
| Return on year-end equity | 15.8% | -5.2% | 6.6% | -3.5% |
| Shares outstanding | n/a | 117.72M | 1.44B | 496.98M |
Revenue, most recent five fiscal years
| Fiscal year | Axalta Coating Systems Ltd. | Albemarle Corp | BeOne Medicines Ltd. | Elanco Animal Health Inc |
|---|---|---|---|---|
| Latest | $5.12B Ended 2025-12-31 | $5.14B Ended 2025-12-31 | $5.34B Ended 2025-12-31 | $4.71B Ended 2025-12-31 |
| 1 year earlier | $5.28B Ended 2024-12-31 | $5.38B Ended 2024-12-31 | $3.81B Ended 2024-12-31 | $4.44B Ended 2024-12-31 |
| 2 years earlier | $5.18B Ended 2023-12-31 | $9.62B Ended 2023-12-31 | $2.46B Ended 2023-12-31 | $4.42B Ended 2023-12-31 |
| 3 years earlier | $4.88B Ended 2022-12-31 | $7.32B Ended 2022-12-31 | $1.42B Ended 2022-12-31 | $4.41B Ended 2022-12-31 |
| 4 years earlier | $4.42B Ended 2021-12-31 | $3.33B Ended 2021-12-31 | $1.18B Ended 2021-12-31 | $4.76B Ended 2021-12-31 |